Lonza launches updated 4D-Nucleofector platform


The latest version of the technology maintains the same level of performance but enhances ease-of-use, the company says

Lonza has launched the next generation of its Nucleofector platform for non-viral cell transfection, which the company says can be used even for hard-to-transfect cells, such as primary cells and pluripotent stem cells.

Now, with an updated core unit and more intuitive software, the 4D-Nucleofector platform offers the same performance with greater ease of use.

Electroporation, the method by which DNA, RNA or protein is introduced into cells through an electrical pulse to change their genotype or phenotype, is a tool used in disease research and drug discovery, as well as in the advancement of gene therapies, immunotherapies and stem cell generation. Lonza’s technology reportedly achieves high transfection efficiency in union with high cell viability by providing unique electrical pulses, cell type-specific solutions, and optimised protocols to target the cell’s nucleus directly.

The 4D-Nucleofector core unit can operate up to three functional modules, allowing for tailored setups and facilitating scale-up from low to high volume transfection. In this iteration, the family of units is now joined by an integrated 96-well unit to suit users with mid-scale transfection requirements for up to 96 samples at once.

In addition, the updated core unit features an 8-inch touchscreen display, enabling users to set up experiments and control all functional modules via the system’s software. Optimised protocols are available for more than 750 different cell types and are designed to provide robust transfection conditions.

Sign up for your free email newsletter

Dr Nina Novak, Product Manager for Nucleofection technology, Lonza, said: "The Nucleofector technology has been used for more than 10,000 peer-reviewed publications since its introduction 20 years ago, clearly demonstrating its importance for this community of successful researchers. The system is widely recognised as the most efficient non-viral cell transfection method – especially for hard-to-transfect cells, such as immune cells. The next-generation 4D-Nucleofector platform brings UX improvements that make the system even more intuitive and easy to use, firmly securing its place as a core method in cell-based research."

Featured Companies